<DOC>
	<DOCNO>NCT01485614</DOCNO>
	<brief_summary>The purpose study assess safety addition sitagliptin , effect hemoglobin A1c ( A1C ) pediatric participant 10-17 year age type 2 diabetes mellitus ( T2DM ) inadequate glycemic control . The primary hypothesis study sitagliptin reduces A1C placebo 20 week treatment .</brief_summary>
	<brief_title>Study Assess Safety &amp; Efficacy Sitagliptin Initial Oral Therapy Treatment Type 2 Diabetes Mellitus Pediatric Participants . ( MK-0431-083 )</brief_title>
	<detailed_description>This trial approximately 56 week duration , include screen period 1 week , 1-week single-blind placebo run-in period , 20-week placebo-controlled , double blind treatment period [ Phase A ] 34-week double-blind active control treatment period [ Phase B ] participant randomize placebo arm initiate glycemic rescue therapy metformin Phase A receive metformin ( blinded manner ) . A telephone contact perform 14 day last dose study medication assess serious adverse event ( SAEs ) . Two arm study remove study protocol amendment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus ( T2DM ) Has receive treatment antihyperglycemic agent ( AHA ) ≥12 week prior Screening Visit/Visit 1 , stable dose insulin ( without AHA ) least 12 week prior Screening Visit/Visit 1 . At screen , participant insulin dos stable insulin dos adjust eligible participate dose remain stable ≥12 week , meet eligibility criterion . In India , participant stable dos insulin eligible . An A1C ≥6.5 % ≤10.0 % ( For participant insulin : A1C ≥7.0 % ≤10.0 % ) . History type 1 diabetes mellitus , autoimmune diabetes mellitus positive antibody screen antiGAD ( Glutamic Acid Decarboxylase ) ( Islet cell autoantigen ) ICA512 . Known monogenic diabetes , secondary diabetes , genetic syndrome disorder know affect glucose tolerance diabetes . Symptomatic hyperglycemia and/or moderate large ketonuria and/or positive test ketonemia require immediate initiation antihyperglycemic therapy . Previously take DPP4 ( Dipeptidyl peptidase4 ) inhibitor ( sitagliptin , vildagliptin , alogliptin , saxagliptin ) ( Glucagonlike peptide1 ) GLP1 receptor agonist ( exenatide liraglutide ) . Hypersensitivity contraindication ( accord product circular country investigational site ) metformin . Chronic treatment medication know cause weight gain within 30 day study start weight loss increase blood glucose within 8 week study start treat antipsychotic within past 12 week . On weight loss program maintenance phase undergone bariatric surgery within 12 month prior study start . On likely require treatment ≥14 consecutive day repeat course pharmacologic dos corticosteroid . Undergone surgical procedure within prior 4 week major surgery plan study . History congenital heart disease cardiovascular disease hypertension . Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease . Active nephropathy ( i.e. , nephrotic syndrome glomerulonephritis ) . Chronic myopathy , mitochondrial disorder , progressive neurological neuromuscular disorder ( e.g. , polymyositis , multiple sclerosis ) . Human immunodeficiency virus ( HIV ) assess medical history . Clinically significant hematological disorder ( aplastic anemia , thrombocytopenia , myeloproliferative myelodysplastic syndrome ) . Under treatment hyperthyroidism . Exhibits abnormal growth pattern treat growth hormone . History malignancy clinically important hematologic disorder . History idiopathic acute pancreatitis chronic pancreatitis . Known history recreational illicit drug use , alcohol abuse dependence ( within past year ) . Donated blood product phlebotomy &gt; 10 % estimate total blood volume within 8 week sign informed consent , intend donate blood product receive blood product within project duration study . Pregnant , positive urine pregnancy test Screening Visit/Visit 1 , expect conceive within project duration study , breastfeed . Exclusionary laboratory value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>